Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07525375 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
A Phase 2 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT07525375 is a Phase 2 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 69 participants.
The verdict
NCT07525375, a Phase 2 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with asthma.
Interventions
- COMBINATION_PRODUCT GP MDI
- COMBINATION_PRODUCT BFF MDI
- COMBINATION_PRODUCT Placebo MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2026-04-14 |
| Est. Completion | 2029-05-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07525375
The ClinicalTrials.gov registry entry for NCT07525375 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GP MDI is the first listed.
NCT07525375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07525375 about?
NCT07525375 is a clinical study titled "A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma". The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with asthma.
What is the current status of trial NCT07525375?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2026-04-14. Estimated completion is 2029-05-23.
What interventions are being tested in trial NCT07525375?
The interventions under investigation include: GP MDI (COMBINATION_PRODUCT), BFF MDI (COMBINATION_PRODUCT), Placebo MDI (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07525375?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.